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Main Text:
Most compounds that target the ribosome affect a large number of mRNAs through general inhibition of translation initiation or elongation (1-3). Furthermore, these compounds almost exclusively act as broad-spectrum inhibitors, displaying little sequence specificity (4) . Many studies have revealed how these compounds bind the translating ribosome and inhibit its function (5) (6) (7) (8) (9) . Recently, we described the small molecule PF846 that selectively blocks translation of individual mRNAs by human ribosomes (10, 11) . However, a mechanism to account for the ability of PF846 to selectively inhibit human protein synthesis remains unknown.
PF846 blocks production of proprotein convertase subtilisin/kexin type 9 (PCSK9)-an important target for regulating plasma low-density lipoprotein cholesterol levels-by interfering with the elongation phase of translation (11) (12) (13) . PF846 selectively stalls the ribosome on very few translated protein nascent chains, generally early in their formation and with no definitive sequence pattern (11) . To gain insight into the mode of action of PF846 in targeting the human ribosome and specific nascent chains, and to identify principles for future drug development, we determined structures of PF846 stalled ribosome nascent chain (RNC) complexes using single-particle cryo-EM.
Since the stalling sequences in most proteins affected by PF846 occur near the Nterminus and would therefore reside in the ribosome exit tunnel (11), we first identified conditions for affinity purification of stable PF846-stalled RNCs from in vitro translation reactions in human cell extracts. The calcium-dependent cell-cell adhesion glycoprotein Cadherin-1 (CDH1) (11, 14) is stalled near its C-terminus by PF846, enabling the extension of the peptide N-terminus beyond the confines of the ribosomal exit tunnel.
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Appending an N-terminal affinity tag followed by the CDH1 cadherin-V domain and the nascent chain sequences targeted by PF846 did not disrupt the ability of PF846 to stall translation and allowed formation and purification of stable PF846-stalled RNCs (Fig.   1A, 1B, fig. S1 ).
To investigate how PF846 stalls specific nascent chain sequences in the human ribosome, we used cryo-EM to determine structures of PF846-stalled CDH1 or PCSK9 ribosome nascent chain complexes (CDH1-RNC or PCSK9-RNC, respectively) ( fig. S2,   fig. S3 , table S1). In both CDH1-RNC and PCSK9-RNC samples, particle sorting of the purified RNCs revealed two populations of ribosomes in the rotated state: one with A/A site peptidyl-tRNA (i.e. nascent chain-tRNA, or NC-tRNA), and the other with hybrid A/P site NC-tRNA. Both also included tRNA in the hybrid P/E site and PF846 bound in the ribosome exit tunnel (Fig. 1C, fig. S4A and S4B) . The following analyses describe the CDH1-RNCs due to the higher-quality CDH1-RNC cryo-EM maps, although we observe similar behavior for the PCSK9-RNCs, as shown in the supplementary figures.
The CDH1-RNC complexes with hybrid A/P site NC-tRNA or with A/A site NCtRNA yielded cryo-EM maps with an average resolution of 3.7 Å and 4.3 Å, respectively (Fig. 1C, 1D and fig. S2 ). The hybrid A/P NC-tRNA represents a mixture of tRNAs, as inferred from the EM map density for nucleotide bases in the codon-anticodon base pairs ( fig. S5 and fig. S6 ), consistent with the clustering of stall sites spanning multiple codons observed by ribosome profiling (11) . We also observed a small population of stalled RNCs in the non-rotated state bearing a P/P-site NC-tRNA and PF846 in our samples ( fig. S2, fig. S3 and fig. S4C ). Interestingly, this population appeared in higher abundance when the RNC sample was purified using a short isolation time prior to Li et al.
making cryo-EM grids (fig. S3B).
These results suggest that the non-rotated RNC is a transient state during PF846 mediated translation stalling. Collectively, our findings suggest that PF846 preferentially stalls RNCs in the rotated state, while the non-rotated state with P/P-site NC-tRNA can be resolved during translation in the presence of PF846.
In the rotated-state RNCs with A/P NC-tRNAs, PF846 occupies a binding pocket in a groove of the ribosomal exit tunnel formed by universally conserved 28S rRNA nucleotides (15) and a stretch of the stalled nascent chain (Fig. 2) . PF846 was fit to the density by evaluating its X-ray structures (11) 
Consistent with PF846 binding to non-translating 80S ribosomes (11), contacts with 28S
rRNA make up the bulk of the small molecule interactions with the ribosome (Fig. 2, fig.   S7 ). The piperidine ring extends into the rRNA binding pocket, contacting nucleotides C1576, G1577, G1579, A1583 and U1584 (Fig. 2E) . The chloro-pyridine and amide linkage also form hydrogen bonds with highly conserved nucleotides G1577 and G1579 ( Fig. 2F and 2G) . Additionally, the interaction is stabilized by U4517, which forms a stacking interaction with the chloro-pyridine ring (Fig. 2H) . To explore the structural basis for PF846 action on eukaryotic but not bacterial ribosomes (11), we aligned the small molecule-binding pocket with the corresponding region in the E. coli ribosome ( Fig. 2A, 2B and fig. S8 ). Phylogenetic analysis revealed key changes to the nucleotide pattern in 23S rRNA in the large ribosomal subunit of bacteria (15) (Fig. 2A and 2B) .
Whereas nucleotides C1576, G1577 and G1579 in the human ribosome are highly complementary to the conformation of PF846 (Fig. 2F and 2G) , nucleotides N1-methylLi et al.
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G745 and ψ746 in bacterial 23S rRNA would clash with the compound ( fig. S8C and   S8D ). Furthermore, whereas U4517 in the human ribosome stacks on the chloropyridine ring in PF846 (Fig. 2H) , the corresponding nucleotide in bacterial 23S rRNA (U2609) would sterically clash with PF846 ( fig. S8E) . Taken together, these distinctions in nucleotide identity and positions help explain PF846's specificity for eukaryotic ribosomes.
The triazolopyridine ring system of PF846 faces the ribosome tunnel and is the only part of the molecule with direct interaction with the stalled nascent chain (Fig. 3,   fig. S9 and S10) . Notably, the triazolopyridine moiety has incomplete density that may be caused by the flexibility of this region during nascent chain elongation ( fig. S7) .
Interestingly, the density for the nascent chains in the RNCs with A/P NC-tRNA was mostly well defined in the ribosome exit tunnel with a local resolution of ~4 Å, although they are likely comprised of different sequences superimposed on each other corresponding to the cluster of stalled states spanning multiple mRNA codons ( fig. S5 and S6) (11) . Both the CDH1 and PCSK9 nascent chains have similar geometry and adopt a predominantly extended conformation in the exit tunnel (16) (fig. S9 and S10) .
The nascent chain spans ~9 residues between the C-terminus of the nascent chains bonded to the 3'-CCA end of A/P site tRNA in the peptidyl transferase center (PTC) and the small molecule binding site (Fig. 3A and fig. S10 ). These residues engage in multiple interactions with nucleotides in 28S rRNA of the 60S subunit, including U4493, U4414, and A3879 (Fig. 3A and fig. S10 ). Past the compound-binding pocket (i.e. in the N-terminal direction), the nascent chain is stabilized by ribosomal proteins uL4 and uL22, along with A1582 and C2773 in 28S rRNA (Fig. 3A and fig. S10 ). Most reported Li et al.
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RNC structures have "kinks" in the ribosome exit tunnel proximal to the PTC (17) . The CDH1 and PCSK9 nascent chains also have a kink in their structures between the PTC active site and PF846-binding pocket (Fig. 3A, figS9 and fig. S10 ), but these adopt a different geometry when compared to stalled human cytomegalovirus (hCMV) and signal recognition particle (SRP) nascent chains (18, 19) (Fig. 3B and 3C) . In the CDH1-RNC and PCSK9-RNC structures, the "kinks" assume more acute angles, to make enough space for the bound small molecule (Fig. 3A, fig. S9 and S10) , whereas the hCMV and SRP NC positions would occlude PF846 binding ( Fig. 3B and 3C ).
PF846 stalls translation of the ribosome predominantly in the rotated state, yet somehow blocks the action of eEF2, the GTPase which promotes mRNA and tRNA translocation to the next codon position (20). In bacterial translation, which is better understood (21, 22) , translocation proceeds through a series of ribosome rotated states, in which the peptidyl-tRNA body and 3'-CCA end move independently from one another, transiting from an A/A site with 3'-CCA end base pairing with the large subunit rRNA Aloop, to an A/A site with 3'-CCA end base pairing with the large subunit rRNA P-loop, and finally to an A/P site with 3'-CCA base pairing with the P-loop (23) . At this point, EF-G (the bacterial homologue of eEF2) can catalyze the remaining conformational changes required for complete translocation of the mRNA and tRNAs (21, 22) . In the PF846-stalled complexes, we observe populations with A/A and A/P NC-tRNAs.
However, the A/P-tRNA exhibits flexible base pairing of the 3'-CCA end with the ribosomal P-loop (Fig. 4, fig. S11 ). We propose that PF846 inhibits rapid translocation of specific nascent chains by preventing the peptidyl-tRNA from binding stably in the Li et al.
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hybrid A/P site, which requires the tRNA 3'-CCA end to properly base pair with 28S rRNA nucleotides in the P-loop.
The present structures of PF846-stalled CDH1 and PCSK9-RNCs provide the first molecular detail for the selective stalling of nascent chains in human ribosomes by a small molecule. PF846 binds a newly-identified small molecule-binding pocket in the exit tunnel of the human ribosome and traps select RNCs predominantly in the rotated state (Fig. 4C) . However, redirection of the nascent chain by PF846 seems to prevent stable base pairing of the NC-tRNA 3'-CCA end with the ribosomal P-loop, likely making these RNCs poor substrates for the GTPase eEF2 responsible for mRNA and tRNA translocation. Stalling of RNCs in the rotated state may be a critical determinant of PF846 selectivity by also evading cellular quality control pathways that recognize aberrantly stalled ribosomes and initiate recycling (24) (25) (26) (27) (28) . For example, Pelota (PELO, Dom34 in yeast) and its cofactors are involved in ribosome-associated quality control pathways that recognize stalled ribosome with an empty A site, to which Pelota binds and promotes ribosome subunit dissociation (29-33). Consistent with the hypothesis that quality control pathways resolve PF846-stalled RNCs, ribosome profiling experiments did not reveal a buildup of stalled RNCs in cells treated with PF846 (11).
The experimental methods presented here provide a means for probing the sequence specificity of PF846-like compounds, and should enable the discovery of other compounds that target the translating human ribosome for therapeutic effect. 
